Genistein Prevents Bone Resorption Diseases by Inhibiting Bone Resorption and Stimulating Bone Formation
Open Access
- 1 January 2003
- journal article
- Published by Pharmaceutical Society of Japan in Biological & Pharmaceutical Bulletin
- Vol. 26 (6), 780-786
- https://doi.org/10.1248/bpb.26.780
Abstract
Genistein, a soybean-derived isoflavone, has been shown to suppress osteoclastic bone resorption. To clarify the mechanisms underlying this action, we investigated the effects of genistein on the differentiation, cytoskeleton and function in mice osteoclasts in vitro and bone metabolism in ovariectomized rats. Study design: Primary OCs were isolated from 3 week-old mice and induced by 1,25(OH)2D3. Then OCs were exposed to genistein at various concentration of 0 M, 10−9 M, 10−8 M, 10−7 M, 10−6 M, and 10−5 M. The number of TRAP+ cells were counted as well as the surface area of bone resorption on bone slice. F-actin change was observed by Confocal. In vivo, forty 12 week-old female SD rats were randomly assigned to four groups: (1) sham operated (Sham); (2) (OVX); (3) ovariectomized and treated with estradiol (OVX-E); (4) ovariectomized and received genistein (OVX-G). After 12 weeks, BMD, body weight, serum level of alkaline phosphatase (ALP), acid phosphatase (ACP), osteocalcin (OC), IL-1β, TNFα, IL-6 and calcitonin (CT) were evaluated. Femur were sectioned. In addition, the serum estradiol, the weight of uteri and histological behavior were also examined to indicate the side effect of genistein to the uteri. Results: In vitro, the number of TRAP+ cells decreased depending on the concentration of genistein as well as the area of bone resorption. F-actin became disorder under Confocal. In vivo, after treated with genistein, BMD and the serum level of ALP, ACP, osteocalcin increased significantly, while the serum level of IL-1β and TNFα decreased. Especially, the increase of ALP and osteocalcin of OVX-G was higher than that of OVX-E. Histologically, the pachy-trabecula were observed as well as the more mineral deposition lines. Additionally, the uterus weight index and the serum estradiol in OVX-G rats were lower significantly than those of OVX-E. The epithelia of uteri gland in OVX-G appeared cubic while those of OVX-E became squamous. Conclusions: Genistein can prevent bone resorption diseases by the promotion of bone formation and the prevention of bone resorption with slight side effect.Keywords
This publication has 27 references indexed in Scilit:
- Emerging therapies in osteoporosisBest Practice & Research Clinical Rheumatology, 2001
- Serum Interleukin 6 Is a Major Predictor of Bone Loss in Women Specific to the First Decade Past MenopauseJournal of Clinical Endocrinology & Metabolism, 2001
- Suppressive Effects of Genistein Dosage and Resistance Exercise on Bone Loss in Ovariectomized Rats.Journal of PHYSIOLOGICAL ANTHROPOLOGY and Applied Human Science, 2001
- Selective Effects of Genistein, a Soybean Isoflavone, on B-Lymphopoiesis and Bone Loss Caused by Estrogen DeficiencyEndocrinology, 1999
- Mandibular bone mineral density as a predictor of skeletal osteoporosisThe British Journal of Radiology, 1996
- Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacementJournal of Clinical Endocrinology & Metabolism, 1995
- Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice.JCI Insight, 1994
- Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.JCI Insight, 1994
- Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawalEndocrinology, 1993
- Perspectives: Interleukin-6: An osteotropic factor?Journal of Bone and Mineral Research, 1992